Quality of Medicines: Introduction Tuesday, 17 November 2009

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.

1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.

1 |1 | Advanced Technical Briefing Seminar : Quality Assurance and Safety of Medicines: Promoting Global Collaboration. 25–29 June 2012, WHO Headquarters,

WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.

Challenges & responses for malaria in Asia

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Essential Drugs Programme

1 Department of Essential Medicines and Pharmaceutical Policies, Health Systems and Services World Health Organization's Prequalification Program for medicines.

TANZANIA August Note on Choice of Comparator Products: Current status Note to Applicants on Choice of Comparator Products in the Prequalification.

Short Update WHO Essential Medicines and Health products IPC Meeting 4 to 6 June 2014.

1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines.

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.

PUBLIC HEALTH PROGRAMMES & PHARMACOVIGILANCE Shanthi Pal Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies World.

Tuberculosis (T.B.) Randy Kim.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:

European and Developing Countries Clinical Trials Partnership AEMI Seminar Dec 2010 Dr Thomas Nyirenda South-South Networking and Capacity Development.

Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:

1 32nd WHO South-East Asia Advisory Committee on Health Research Bangkok, Thailand, October 2011 Review of work carried out by Subcommittee on Vaccines.

XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…

General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM)

Regulation of medicines and other health technologies. The future of regulation, where are we going? EMP TBS November 2014, Geneva Dr Lembit Rägo Head,

World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.

Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.

1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:

Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:

1 |1 | Technical Briefing Seminar, November 2010 WHO Headquarters, Geneva, Switzerland Dr Samvel Azatyan Manager, Medicines Regulatory Support Programme.

Evaluating the Effectiveness of TB Medicine Supply Management Training in Western Cape, South Africa Fathima Fyzoo 1 ; Margaret von Zeil 2 1.Management.

| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.

Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO

1 Department of Essential Medicines and Pharmaceutical Policies Introduction to Medicines Quality Assurance and Safety Dr Lembit Rägo Coordinator Quality.

Strategies to promote uptake of appropriately formulated paediatric TB drugs Dr Malgosia Grzemska Global TB Programme World Health Organization, Geneva,

WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.

Dr Mary Couper Quality Assurance and Safety of Medicines WHO

Second African Medicines Regulators Conference^, 24 ‐ 26 November 2009, Maputo, Mozambique, Prequalification of Medicines Dr Lembit Rägo, Coordinator Quality.

1 Department of Essential Medicines and Pharmaceutical Policies Medicines Regulation: Introduction Dr Lembit Rägo Coordinator Quality Assurance and Safety:

By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.

Dr R. Balocco Mattavelli, INN Programme Manager Informal Consultation on Medical devices, March 2011 INN Programme Dr Raffaella Balocco Mattavelli.

Global Health Governance. 8 Millennium Development Goals.

Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?

The INN Programme and the INN Global Hub

STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL

Community Representative Update

Efficacy and Safety of Medicines

Palliative Care and M/XDR-TB Global burden of M/XDR-TB

Global Drug Facility An innovative approach to supplying anti-TB drugs

Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.

The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.

Quality Assurance and Safety of Medicines

André van Zyl (M. Pharm, Ph.D, Ph. D) Head of Inspections

وضعیت بیماری سل در جهان، منطقه و ایران

World Health Organization

بیماری سل TUBERCULOSIS

Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.

Key issues in DOTS implementation

Richard Laing, Kelly McGoldrick

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

Medicines Regulation: Introduction

Quality Problems with Antimalarials

Prequalification of essential medicines

WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:

Assessment of Medicines

Jitka Sabartova WHO Prequalification of Medicines Programme

Treatment of Drug Resistant TB - Questions

Pharmacovigilance.

An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Presentation transcript:

Quality of Medicines: Introduction Tuesday, 17 November 2009 Dr Lembit Rägo, Coordinator Quality Assurance and Safety: Medicines (QSM), Department of Essential Medicines and Pharmaceutical Policies (EMP) World Health Organization Geneva, Switzerland ragol@who.int

The Millennium Development Goals (MDGs) are eight international development goals that 192 United Nations member states and at least 23 international organizations have agreed to achieve by the year 2015

Is quality of medicines still Globally a problem? Facts Diethylene glycol poisonings continue Roche Viracept (nelfinavir) case Heparin case …

Can we rely on essential medicines against TB? (1) 2008: South-Africa Drug Regulatory Authority withdraws from the market two FDCs (Pyrazinamide-Ethambutol-INH-Rifampicin and INH-Rifampicin) produced in India. "Substandard tuberculosis medicines are particularly worth highlighting: there is little point in deciding optimum treatment regimens for TB when the medicines the patients actually use are not curative and/or encourage the spread of drug resistance" Paul Newton (BMJ 23.8.2008: 427)

Can we rely on essential medicines against TB? (2) Quality defects found in: Botswana: 4/13 FDCs Nigeria: 4/4 INH, 3/3 Pyr, 5/15 Rif and 10/19 Strep inj India: Amikacin, Etham (2x), Rif (2x), INH (2x), Pyr Myanmar: Rifampicin Hong Kong, Pakistan, Germany: Ofloxacin Rifampicin: Poor bioavailability in FDCs and monotherapy WHO study planned on the use and quality of TB medicines with NDRAs in Azerbaijan, Belarus, Kazakhstan, Ukraine, Uzbekistan

Quality failures The Daily Star, 2008-11-19 Drug marketed to cure or kill? Foreign particle, circled, is seen in a 500mg ampoule of Amibac (amikacin) intravenous injection. Photo: STAR

Medicines and blood products/related bilologicals – QSM/EMP Who in WHO are dealing with quality, safety, efficacy and regulatory issues of medicines? Medicines and blood products/related bilologicals – QSM/EMP Vaccines and other biologicals – QSS/IVB … some other "pockets"

Quality Assurance and Safety: Medicines (QSM) team One team, 7 inter-related programmes Quality Assurance (Dr Sabine Kopp) International Nonproprietary Names (Dr Raffaella Balocco) Quality Assurance of Blood Products and Realated Biologicals (Dr Ana Padilla) Safety (Pharmacovigilance) (Dr Mary Couper) Regulatory Support (Dr Samvel Azatyan) Anticounterfeiting (Dr Sabine Kopp) Prequalification of medicines (Dr Anthony Gould)

Biennial International Conference of Drug Regulatory Authorities (ICDRA) – forum for 100+ nations